Back to Journals » Clinical Ophthalmology » Volume 1 » Issue 3

Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis

Authors Joseph R Ferencz, Eli Rosen, Guy Tam, Gila Gilady, Alexander Rubowich, et al

Published 15 December 2007 Volume 2007:1(3) Pages 347—351



Joseph R Ferencz1, Eli Rosen1, Guy Tam1, Gila Gilady1, Alexander Rubowich1, Ehud I Assia1, Ze’ev Korzets2

1Department of Ophthalmology and 2Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel; 1,2Sackler Medical School, Tel Aviv University, Tel Aviv, Israel

Objective: To report on the use of intravitreal bevacizumab (an anti-vascular endothelial growth factor [VEGF] monoclonal antibody) as treatment of diffuse exudative retinal detachment due to ischemic central retinal vein occlusion (CRVO).

Design: Interventional case report.

Patient: A 27-year old woman on peritoneal dialysis because of end stage renal failure (ESRF) due to perinuclear antineutrophil cytoplasmic antibody (p-ANCA) associated vasculitis presented with acute unilateral blurred vision. Visual acuity (VA) rapidly deteriorated. Examination revealed the development of total bullous exudative retinal detachment following ischemic CRVO.

Intervention: Two intravitreal injections of bevacizumab (2.5 mg/0.1ml) were administered followed by panretinal laser photocoagulation.

Main outcome measures: VA, retinal detachment, and changes in macular edema.

Results: Prompt significant resolution of exudative retinal detachment with a corresponding gradual improvement of VA from light perception to finger counting. At follow-up examination after 8-months, the retina remained attached.

Conclusion: Intravitreal bevacizumab proved to be a useful treatment modality in diffuse exudative retinal detachment due to CRVO.

Keywords: bevacizumab, CRVO, exudative retinal detachment, p-ANCA vasculitis